Viridian Therapeutics

140 articles with Viridian Therapeutics

• Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

  5/12/2022

  Viridian Therapeutics, Inc. announced financial results for the first quarter ending March 31, 2022 and provided corporate updates, including interim results for the healthy volunteer portion of the Company’s ongoing proof of concept trial of VRDN-001 in Thyroid Eye Disease.

• Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

  5/3/2022

  Viridian Therapeutics, Inc. today announced it will report its financial results from the first quarter ended March 31, 2022, after the financial markets close on Thursday, May 12, 2022.

• Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

  4/6/2022

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, which includes a presentation beginning at 4:30 p.m. ET.

• Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

  4/4/2022

  Viridian Therapeutics, Inc. announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. for up to $75 million.

• Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

  3/21/2022

  Viridian Therapeutics, Inc. announced that it has dosed the first subject in a Phase 1 clinical trial evaluating VRDN-002 for the treatment of thyroid eye disease.

• Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

  3/14/2022

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022.

• Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

  3/10/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided corporate updates.

• Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

  3/3/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2021, after the financial markets close on Thursday, March 10, 2022.

• Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

  2/14/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference.

• Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

  1/31/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application of VRDN-002.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

  1/4/2022

  Viridian Therapeutics, Inc. announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for VRDN-002, a humanized monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection for the treatment of thyroid eye disease (TED).

• Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

  12/20/2021

  Viridian Therapeutics, Inc. today announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001.

• Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 30, 2021

  11/30/2021

  Viridian Therapeutics, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of stock options to purchase an aggregate of 180,000 shares of the Company’s common stock to two new employees on the date that each employee commences service with the Company.

• Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

  11/15/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), today announced the U.S. Food and Drug Administration (“FDA”) clearance of its Investigational New Drug (“IND”) application for VRDN-001, which the Company is developing for the treatment of thyroid eye disease (TED).

• Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

  11/4/2021

  Viridian Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2021, and provided corporate updates.

• Viridian Therapeutics to Present at Upcoming Investor Conferences - Nov 03, 2021

  11/3/2021

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Credit Suisse 30th Annual Healthcare Conference and participate in fireside chats at the Jefferies London Healthcare Conference and the Evercore ISI 4th Annual HealthCONx Conference.

• Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

  10/14/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases underserved by today's therapies, announced today the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA).

• Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

  9/30/2021

  Viridian Therapeutics, Inc. announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association (ATA), which is being held from September 30th through October 3rd .

• Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

  9/23/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the closing of an underwritten public offering of 7,344,543 shares of common stock,